Duality Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others in China and internationally. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It has strategic partnerships with BioNTech SE to develop therapies to complement or replace chemotherapy; BeOne to develop and commercialize DB-1312, an in-house discovered B7-H4- targeted ADC; and Genentech, Inc. to develop antibody-drug conjugates. The company was incorporated in 2019 and is headquartered in Shanghai, China.
Frequently asked questions
What sector does Duality Biotherapeutics Inc (9606) operate in?
Duality Biotherapeutics Inc belongs to the Other sector and operates in the Biotechnology industry.
What is Duality Biotherapeutics Inc (9606) current stock price?
As of the latest data, Duality Biotherapeutics Inc stock price is HK$109.10, with a previous close of HK$147.50. Duality Biotherapeutics Inc lost -HK$38.40 in the last trading session, representing a -26.03% loss.
What is Duality Biotherapeutics Inc (9606) current market capitalization?
Duality Biotherapeutics Inc market cap is approximately 9.97 billion.
What is Duality Biotherapeutics Inc (9606) EBITDA?
Duality Biotherapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -479.85 million.
Does Duality Biotherapeutics Inc (9606) pay dividends?
No. Duality Biotherapeutics Inc does not pay a dividend.
What is Duality Biotherapeutics Inc (9606) beta (volatility) score?
Duality Biotherapeutics Inc has a beta of -0.104, indicating lower volatility than the overall market.
